Evaluation of tumor- and stromal immune marker heterogeneity in non-small cell lung cancer

被引：0
|
作者：
Casadevall Aguilar, D. [1 ]
Pijuan, L. [2 ]
Clave, S. [2 ]
Taus, A. [1 ]
Hernandez, A. [1 ]
Lorenzo, M. [2 ]
Mojal, S. [3 ]
Menendez, S. [2 ]
Albanell, J. [4 ]
Salido, M. [4 ]
Arriola, E. [4 ]
机构：
[1] Univ Hosp del Mar, Med Oncol, Barcelona, Spain
[2] Univ Hosp del Mar, Pathol, Barcelona, Spain
[3] Inst Hosp Mar Invest Med IMIM, AMIB, Barcelona, Spain
[4] Inst Hosp Mar Invest Med IMIM, Canc Res Program, Barcelona, Spain
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw363.65
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
117P
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Circulating Tumor Cell as a Predictive Marker for Immunotherapy in Advanced Non-Small Cell Lung Cancer
    Park, C.
    Oh, H.
    Kim, M.
    Kim, B.
    Cho, H.
    Oh, I.
    Kim, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S418 - S418
  • [22] Evaluation of Tumor Heterogeneity (TH) as a Prognostic Biomarker in Osimertinib treated Non-Small Cell Lung Cancer Patients
    Murugesan, K.
    Wong, K. -K.
    Tolba, K.
    Oxnard, G.
    Hegde, P.
    Frampton, G.
    Montesion, M.
    Fabrizio, D.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S441 - S441
  • [23] Tumor lymphocytic infiltration in non-small cell lung cancer: the ultimate prognostic marker?
    Romero Vielva, Laura
    TRANSLATIONAL LUNG CANCER RESEARCH, 2016, 5 (04) : 370 - 372
  • [24] Inverse prognostic impact of angiogenic marker expression in tumor cells versus stromal cells in non-small cell lung cancer
    Donnem, Tom
    Al-Saad, Samer
    Al-Shibli, Khalid
    Delghandi, Marit P.
    Persson, Magnus
    Nilsen, Marit N.
    Busund, Lill-Tove
    Bremnes, Roy M.
    CLINICAL CANCER RESEARCH, 2007, 13 (22) : 6649 - 6657
  • [25] Immune Signatures of Non-Small Cell Lung Cancer
    Green, Susan
    Dawe, David E.
    Banerji, Shantanu
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (06) : 913 - 915
  • [26] Tumor- associated fibrosis leads to an increase in T-cell exhaustion and impairs tumor control in non-small cell lung cancer
    Panni, Usman Y.
    Shenoy, Varun
    Knolhoff, Brett
    Ahmed, Faiz
    Herzog, Brett
    Hawkins, William G.
    Olson, John A.
    DeNardo, David G.
    CANCER RESEARCH, 2024, 84 (06)
  • [27] Tumor regression in non-small cell lung cancer
    Junker, K
    Klinke, V
    Bosse, U
    Thomas, M
    Muller, KM
    2ND INTERNATIONAL CONGRESS ON LUNG CANCER, 1996, : 113 - 117
  • [28] Tumor angiogenesis of non-small cell lung cancer
    Shijubo, N
    Kojima, H
    Nagata, M
    Ohchi, T
    Suzuki, A
    Abe, S
    Sato, N
    MICROSCOPY RESEARCH AND TECHNIQUE, 2003, 60 (02) : 186 - 198
  • [29] Dendritic Cell Vaccination in Non-Small Cell Lung Cancer: Remodeling the Tumor Immune Microenvironment
    Abascal, Jensen
    Oh, Michael S.
    Liclican, Elvira L.
    Dubinett, Steven M.
    Salehi-Rad, Ramin
    Liu, Bin
    CELLS, 2023, 12 (19)
  • [30] Local mutational diversity drives intratumoral immune heterogeneity in non-small cell lung cancer
    Jia, Qingzhu
    Wu, Wei
    Wang, Yuqi
    Alexander, Peter B.
    Sun, Chengdu
    Gong, Zhihua
    Cheng, Jia-Nan
    Sun, Huaibo
    Guan, Yanfang
    Xia, Xuefeng
    Yang, Ling
    Yi, Xin
    Wan, Yisong Y.
    Wang, Haidong
    He, Ji
    Futreal, P. Andrew
    Li, Qi-Jing
    Zhu, Bo
    NATURE COMMUNICATIONS, 2018, 9
12345